Management of anticoagulation and factor XIII replacement in a patient with severe factor XIII deficiency and recurrent venous thromboembolic disease: case report and review of literature.

Bounaix, Laura; Schröder, Verena; Fontana, Pierre; Casini, Alessandro (2024). Management of anticoagulation and factor XIII replacement in a patient with severe factor XIII deficiency and recurrent venous thromboembolic disease: case report and review of literature. Research and practice in thrombosis and haemostasis, 8(2) Wiley 10.1016/j.rpth.2024.102371

Preview

Text 1-s2.0-S2475037924000608-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (336kB) | Preview

BACKGROUND

Thrombotic events in congenital factor (F)XIII deficiency are extremely rare. To our knowledge, we describe the first case of severe congenital FXIII deficiency associated with recurrent venous thrombotic events.

KEY CLINICIAN QUESTION

How to deal with anticoagulation treatment in patients with severe FXIII deficiency?

CLINICAL APPROACH

The patient was treated with rivaroxaban and plasma-derived FXIII substitution therapy as prophylaxis without bleeding complications. We aimed at FXIII trough levels of 50% during the loading doses of rivaroxaban, then 30% during the maintenance dose of rivaroxaban, and finally 20% during the long-term use of prophylactic dose of rivaroxaban.

CONCLUSION

Treatment of thrombotic events with rivaroxaban in patients with severe bleeding disorders seems to be safe, requiring an adaptation of the intensity of the replacement therapy.

Interest & Impact

Downloads

6 since deposited on 11 Apr 2024
6 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item